Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U96 in Relapsed/Refractory B-cell Tumors
NCT07511426Phase 1Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of U96 in B-cell acute lymphoblastic leukemia (B-ALL) and B cell lymphoma (8 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Dose-limiting toxicity at 28 days and Adverse Event at 2 years. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
U96
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT07511426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511426.